Abstract: An anti-icing coating is provided having low interfacial toughness (LIT) with ice. The anti-icing coating includes a polymer and a plasticizing agent. A thickness of the anti-icing coating may be less than or equal to about 100 micrometers (?m). Further, the anti-icing coating has an interfacial toughness (?ice) with ice of less than or equal to about 1 J/m2. Such an anti-icing coating may be applied to a substrate or surface of a device on which ice may form, such as aircraft, vehicles, marine vessels, outdoor equipment, snow or ice removal equipment, recreational equipment, wind turbines, telecommunications equipment, power lines, and the like. Methods of forming such anti-icing coatings are also provided.

Abstract: Provided herein are compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, provided herein are non-coding RNAs as diagnostic markers and clinical targets for cancer.

Abstract: A thermoelectric composition is provided that includes a nanocomposite comprising a copper selenide (Cu2Se) matrix having a plurality of nanoinclusions comprising copper metal selenide (CuMSe2) distributed therein. M may be selected from the group consisting of: indium (In), aluminum (Al), gallium (Ga), antimony (Sb), bismuth (Bi), and combinations thereof. The thermoelectric composition has an average figure of merit (ZT) of greater than or equal to about 1.5 at a temperature of less than or equal to about 850K (about 577° C.). Methods of making such a thermoelectric nanocomposite material by a sequential solid-state transformation of a CuSe2 precursor are also provided.

Abstract: Provided herein is an organic photovoltaic device comprising one or ore layers comprising one or more organic and/or organometallic compounds, and one or more of these layers may have a root-mean-square surface roughness ranging from about 2 nm to about 10 nm. Additionally provided is a method of manufacturing an organic photovoltaic device, and may comprise depositing one or more organic and/or organometallic compounds in one or more layers having a root-mean-square surface roughness ranging from about 2 nm to about 10 nm. Also provided is an organic photovoltaic device comprises one or more layers of one or more organic and/or organometallic compounds, the layers are deposited by organic vapor phase deposition, and the PCE may decrease by no more than about 1% after 250 hours of illumination at 1 sun intensity.

Abstract: Disclosed herein are organic photosensitive optoelectronic device comprising a first layer comprising one or more of a first layer material, a second layer comprising one or more of a second layer material, and a third layer comprising one or more of a third layer material. The second layer may be dissolved in a semi-orthogonal solvent. The first layer and the third layer may be very slightly soluble or practically insoluble in the semi-orthogonal solvent.

Abstract: A method of producing uniform multilayer graphene by chemical vapor deposition (CVD) is provided. The method is limited in size only by CVD reaction chamber size and is scalable to produce multilayer graphene films on a wafer scale that have the same number of layers of graphene throughout substantially the entire film. Uniform bilayer graphene may be produced using a method that does not require assembly of independently produced single layer graphene. The method includes a CVD process wherein a reaction gas is flowed in the chamber at a relatively low pressure compared to conventional processes and the temperature in the reaction chamber is thereafter decreased relatively slowly compared to conventional processes. One application for uniform multilayer graphene is transparent conductors. In processes that require multiple transfers of single layer graphene to achieve multilayer graphene structures, the disclosed method can reduce the number of process steps by at least half.

Abstract: The present invention provides a method of treating or preventing immunoinflammatory, vascular, thrombotic or ischemic disorders in a subject, the method comprises administering to the subject an agent which dissipates nucleotide phosphates or generates a product which stimulates adenosine receptors. The present invention also provides a method of treating or preventing immunoinflammatory, thrombotic or ischemic disorders in a subject by inhibiting leukocyte infiltration into a site which comprises administering to the subject an effective amount a described agent. Agents described for use in the methods of the invention include CD73, a fragment a mutant, or a modified form thereof.

Abstract: The present disclosure relates to compositions capable of absorbing UVA and UVB light. In particle, the present disclosure relates to UV screening compositions comprising at least a portion of LITE-1 polypeptides which are capable of absorbing UV light (e.g., UV-A and/or UV-B light).

Abstract: For patients who exhibit or may exhibit primary or comorbid disease, pharmacological phenotypes may be predicted through the collection of panomic data over a period of time. A machine learning engine may generate a statistical model based on training data from training patients to predict pharmacological phenotypes, including drug response and dosing, drug adverse events, disease and comorbid disease risk, drug-gene, drug-drug, and polypharmacy interactions. Then the model may be applied to data for new patients to predict their pharmacological phenotypes, and enable decision making in clinical and research contexts, including drug selection and dosage, changes in drug regimens, polypharmacy optimization, monitoring, etc., to benefit from additional predictive power, resulting in adverse event and substance abuse avoidance, improved drug response, better patient outcomes, lower treatment costs, public health benefits, and increases in the effectiveness of research in pharmacology and other biomedical fields.

Abstract: In order to achieve a system capable of analyzing a wide range of compounds while saving time and energy consumption, a progressive cellular architecture is presented for vapor collection and gas chromatographic separation. Each cell includes a preconcentrator and separation column that are adapted for collecting and separating compounds only within a specific volatility range. A wide volatility range can therefore be covered by the use of multiple cells that are cascaded in the appropriate order. The separation columns within each cell are short enough to reduce the heating and pumping requirements. The gas flow for vapor collection and separation is provided by low-power gas micropumps that use ambient air. The system is also configurable to incorporate capabilities of detecting and reducing vapor overload. The progressive cellular architecture directly address the compromise between low power and broad chemical analyses.

Abstract: Material-Sensing Light Imaging, Detection, And Ranging (LIDAR) systems optionally include a laser configured to generate a light pulse, a beam steerer configured to produce a polarization-adjusted light pulse emitted towards an object, at least one polarizer configured to polarize reflected, scattered, or emitted light returned from the object, and a processor configured to detect at least one material of the object based on an intensity and polarization of the polarized reflected, scattered or emitted light from the object. The beam steerer may include a kirigami nanocomposite. Methods are also provided, including, for example, generating a light pulse, adjusting a polarization of the light pulse to produce a polarization-adjusted light pulse emitted towards an object, polarizing reflected, scattered, or emitted light returned from the object, and detecting at least one material of the object based on an intensity and polarization of the polarized reflected, scattered or emitted light from the object.

Abstract: The present disclosure is directed to HER2-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or cancer cells using the peptide reagents.

Abstract: Devices and systems for analyzing biological samples are provided. Devices include a hollow body extending from a first end to a second end. The body defines a sample collecting portion. A first opening at the first end of the body is operable to receive a source of negative pressure and a second opening at the second end of the body is operable to receive a biological sample. The body also includes an optically transparent region disposed in a region corresponding to the sample collecting portion, the optically transparent region being configured to transmit electromagnetic radiation therethrough from an imaging device capable of imaging the biological sample when disposed in the sample collecting portion.

Abstract: Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.

Abstract: The present disclosure relates to a method for forming solid-state electrolytes, electrodes, current collectors, and/or conductive additives used in solid-state batteries. In one version, the method includes depositing a stabilization coating on a powdered electrolyte material, or a powdered electrode material, or a powdered conductive additive material and forming a slurry comprising the coated material. The slurry is then cast on a surface to form a layer, and the layer is sintered to form a solid state electrolyte, or an electrode, or an electrode having the conductive additive.

Abstract: An ingestible electronic capsule for the collection of samples along a gastric intestinal tract and methods relating thereto are provided. The ingestible electronic capsule includes a housing and a cap that form an interior chamber. The cap includes a sampling port and one or more sample collection chambers are disposed within the interior chamber. A motor is also disposed within the interior chamber and is configured to rotate one of the cap and the one or more sample collection chambers so to align one or the one or more sample collection chambers and the sampling port of the cap so to allow for sample collection. A microcontroller is also disposed within the interior chamber and is in communication with at least the motor. The microcontroller is configured to control the selective alignment of the sampling port and one of the one or more sample collection chambers and induce gastric intestinal fluid sampling.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazoline structure or a quinoline structure which function as dual inhibitors of EGFR proteins and PI3K proteins, and their use as therapeutics for the treatment of cancer and other diseases.

Abstract: An everter device to facilitate preparation of ends of arterial segments for end-to-end microvascular anastomosis. The device includes structure that provides sufficient support to prevent unwanted buckling of arterial tissue. The everter device offsets the tendency of the arterial tissue wall to recover its natural shape and fall off securement posts or pins of a coupler ring. The structure may be in the form of an intraluminal catheter balloon. Alternately, the structure may be in the form of a plunger. Alternately, the structure may be in the form of a radially expanding member provided on a shaft. The device further has a contoured surface on an everter end to evert a free end of arterial tissue over a coupler ring, and to cause the posts or pins of the coupler ring to pierce through the everted arterial tissue. The everter end is provided with one or more openings therein, such as a circumferential slot, to receive the posts or pins of the coupler ring.

Abstract: A droplet-based microfluidic rheometer system and method of use for real-time viscosity monitoring of blood coagulation is disclosed. Droplets of blood samples are generated in a microfluidic rheometer, and the size of the droplets is highly correlated to the sample viscosity. The size of the droplets can be determined optically using an inverted light microscope and a camera or using electrodes. The microfluidic rheometer systems provides viscosity measurements in less than a second and consumes less than 1?{umlaut over (?)} blood or plasma over an hour period. The viscosity measurements may be displayed and transmitted to the Internet or cloud storage.

Abstract: An article for forming an electrochemical device is disclosed. The article comprises a metallic current collector clad with an ion conducting solid-electrolyte material such that intimate contact between the current collector and the ion conducting solid-electrolyte material is made. A lithium metal anode can be formed in situ between the current collector clad and the ion conducting solid-electrolyte material from lithium ions contained within a cathode material that is placed in contact with the ion conducting solid-electrolyte material. A bipolar electrochemical cell can be constructed from the article.